Format
Sort by
Items per page

Send to

Choose Destination

Best matches for methylene blue in Alzheimer:

Search results

Items: 1 to 20 of 70

1.

Highly sensitive aptasensor based on interferometric reflectance spectroscopy for the determination of amyloid β as an Alzheimer's disease biomarkers using nanoporous anodic alumina.

Amouzadeh Tabrizi M, Ferré-Borrull J, Marsal LF.

Biosens Bioelectron. 2019 Jul 15;137:279-286. doi: 10.1016/j.bios.2019.04.050. Epub 2019 Apr 30.

PMID:
31125817
2.

Overview of novel multifunctional agents based on conjugates of γ-carbolines, carbazoles, tetrahydrocarbazoles, phenothiazines, and aminoadamantanes for treatment of Alzheimer's disease.

Makhaeva GF, Shevtsova EF, Boltneva NP, Lushchekina SV, Kovaleva NV, Rudakova EV, Bachurin SO, Richardson RJ.

Chem Biol Interact. 2019 Aug 1;308:224-234. doi: 10.1016/j.cbi.2019.05.020. Epub 2019 May 14. Review.

PMID:
31100279
3.

Azure B affects amyloid precursor protein metabolism in PS70 cells.

Biberoglu K, Yuksel M, Tacal O.

Chem Biol Interact. 2019 Feb 1;299:88-93. doi: 10.1016/j.cbi.2018.11.023. Epub 2018 Nov 28.

PMID:
30500345
4.

Repurposing Proteostasis-Modifying Drugs to Prevent or Treat Age-Related Dementia: A Systematic Review.

Heard DS, Tuttle CSL, Lautenschlager NT, Maier AB.

Front Physiol. 2018 Oct 30;9:1520. doi: 10.3389/fphys.2018.01520. eCollection 2018.

5.

Methylene blue activates the PMCA activity and cross-interacts with amyloid β-peptide, blocking Aβ-mediated PMCA inhibition.

Berrocal M, Corbacho I, Gutierrez-Merino C, Mata AM.

Neuropharmacology. 2018 Sep 1;139:163-172. doi: 10.1016/j.neuropharm.2018.07.012. Epub 2018 Jul 9.

PMID:
30003902
6.

Tau-Targeted Multifunctional Nanocomposite for Combinational Therapy of Alzheimer's Disease.

Chen Q, Du Y, Zhang K, Liang Z, Li J, Yu H, Ren R, Feng J, Jin Z, Li F, Sun J, Zhou M, He Q, Sun X, Zhang H, Tian M, Ling D.

ACS Nano. 2018 Feb 27;12(2):1321-1338. doi: 10.1021/acsnano.7b07625. Epub 2018 Feb 1.

PMID:
29364648
7.

Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.

Wilcock GK, Gauthier S, Frisoni GB, Jia J, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Schelter BO, Wischik DJ, Davis CS, Staff RT, Vuksanovic V, Ahearn T, Bracoud L, Shamsi K, Marek K, Seibyl J, Riedel G, Storey JMD, Harrington CR, Wischik CM.

J Alzheimers Dis. 2018;61(1):435-457. doi: 10.3233/JAD-170560.

8.

A unique and promising combination of medications for the treatment of Alzheimer's disease.

Weinstein JD.

Med Hypotheses. 2017 Nov;109:53-55. doi: 10.1016/j.mehy.2017.09.021. Epub 2017 Sep 24.

PMID:
29150293
9.
10.

Microtubule affinity-regulating kinases are potential druggable targets for Alzheimer's disease.

Annadurai N, Agrawal K, Džubák P, Hajdúch M, Das V.

Cell Mol Life Sci. 2017 Nov;74(22):4159-4169. doi: 10.1007/s00018-017-2574-1. Epub 2017 Jun 20. Review.

PMID:
28634681
11.

Alzheimer's disease in the zebrafish: where can we take it?

Caramillo EM, Echevarria DJ.

Behav Pharmacol. 2017 Apr;28(2 and 3-Spec Issue):179-186. doi: 10.1097/FBP.0000000000000284. Review.

PMID:
28177980
12.

Methylene blue improves streptozotocin-induced memory deficit by restoring mitochondrial function in rats.

Li L, Qin L, Lu HL, Li PJ, Song YJ, Yang RL.

Brain Res. 2017 Feb 15;1657:208-214. doi: 10.1016/j.brainres.2016.12.024. Epub 2016 Dec 27.

PMID:
28034723
13.

Label-Free Electrochemical Biosensor for Monitoring of Chloride Ion in an Animal Model of Alzhemier's Disease.

Dong H, Zhang L, Liu W, Tian Y.

ACS Chem Neurosci. 2017 Feb 15;8(2):339-346. doi: 10.1021/acschemneuro.6b00296. Epub 2016 Dec 19.

PMID:
27992175
14.

Attenuation of synaptic toxicity and MARK4/PAR1-mediated Tau phosphorylation by methylene blue for Alzheimer's disease treatment.

Sun W, Lee S, Huang X, Liu S, Inayathullah M, Kim KM, Tang H, Ashford JW, Rajadas J.

Sci Rep. 2016 Oct 6;6:34784. doi: 10.1038/srep34784.

15.

No "breakthrough" in Alzheimer's disease.

Wise J.

BMJ. 2016 Aug 16;354:i4474. doi: 10.1136/bmj.i4474. No abstract available.

PMID:
27531826
16.

Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease.

Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Lozupone M, Santamato A, Zecca C, Barulli MR, Bellomo A, Pilotto A, Daniele A, Greco A, Logroscino G.

Biomed Res Int. 2016;2016:3245935. doi: 10.1155/2016/3245935. Epub 2016 Jun 26. Review.

17.

Toluidine blue O is a potent inhibitor of human cholinesterases.

Biberoglu K, Tek MY, Ghasemi ST, Tacal O.

Arch Biochem Biophys. 2016 Aug 15;604:57-62. doi: 10.1016/j.abb.2016.06.005. Epub 2016 Jun 11.

PMID:
27296777
18.

Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium.

Seripa D, Solfrizzi V, Imbimbo BP, Daniele A, Santamato A, Lozupone M, Zuliani G, Greco A, Logroscino G, Panza F.

Expert Rev Neurother. 2016;16(3):259-77. doi: 10.1586/14737175.2016.1140039. Review.

PMID:
26822031
19.

Tau Biology and Tau-Directed Therapies for Alzheimer's Disease.

Bakota L, Brandt R.

Drugs. 2016 Mar;76(3):301-13. doi: 10.1007/s40265-015-0529-0. Review.

20.

Caspase-cleaved tau exhibits rapid memory impairment associated with tau oligomers in a transgenic mouse model.

Kim Y, Choi H, Lee W, Park H, Kam TI, Hong SH, Nah J, Jung S, Shin B, Lee H, Choi TY, Choo H, Kim KK, Choi SY, Kayed R, Jung YK.

Neurobiol Dis. 2016 Mar;87:19-28. doi: 10.1016/j.nbd.2015.12.006. Epub 2015 Dec 17.

PMID:
26704708

Supplemental Content

Loading ...
Support Center